CN Patent

CN118043330A — Kras g12d抑制剂化合物及其制备方法和应用

Assigned to Hainan Xiansheng Zaiming Pharmaceutical Co ltd · Expires 2024-05-14 · 2y expired

What this patent protects

公开了作为KRAS G12D抑制剂的化合物或其立体异构体或其可药用盐，所述化合物具有式(I)所示的结构。还公开了所述式(I)化合物或其立体异构体或其可药用盐的制备方法、含有所述化合物或其立体异构体或其可药用盐的药物组合物、以及所述化合物或其立体异构体或其可药用盐在预防或治疗与KRAS G12D突变相关的疾病或病症中的用途。

USPTO Abstract

公开了作为KRAS G12D抑制剂的化合物或其立体异构体或其可药用盐，所述化合物具有式(I)所示的结构。还公开了所述式(I)化合物或其立体异构体或其可药用盐的制备方法、含有所述化合物或其立体异构体或其可药用盐的药物组合物、以及所述化合物或其立体异构体或其可药用盐在预防或治疗与KRAS G12D突变相关的疾病或病症中的用途。

Drugs covered by this patent

Patent Metadata

Patent number
CN118043330A
Jurisdiction
CN
Classification
—
Expires
2024-05-14
Drug substance claim
No
Drug product claim
No
Assignee
Hainan Xiansheng Zaiming Pharmaceutical Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.